Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial
Background: Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is 60 mg, earlier studies of prasugrel su...
Saved in:
| Published in | Clinical therapeutics Vol. 32; no. 2; pp. 365 - 379 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Bridgewater, NJ
EM Inc USA
01.02.2010
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0149-2918 1879-114X 1879-114X |
| DOI | 10.1016/j.clinthera.2010.02.015 |
Cover
Loading…
| Abstract | Background: Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is 60 mg, earlier studies of prasugrel suggested that active-metabolite exposure and pharmacodynamic response may be higher in Asian subjects than in white subjects.
Objectives: This study compared the pharmacodynamic response to a single 30-mg dose of prasugrel in healthy Chinese and white subjects and the response to a single 30-mg dose of prasugrel and a single 300-mg dose of clopidogrel in healthy Chinese subjects. The pharmacokinetics and tolerability of both drugs were also assessed.
Methods: This was an open-label, single-dose study conducted in Singapore. Chinese subjects were randomly allocated to receive prasugrel 30 mg or clopidogrel 300 mg; after a 14-day washout period, they received the alternative drug. White subjects received only prasugrel 30 mg. Blood samples for pharmaco-dynamic assessments were collected before dosing and at 0.5, 1, 2, 4, and 24 hours after dosing. Three methods were used to measure inhibition of platelet aggregation (IPA)—traditional light transmission aggregometry (LTA), the Verify
Now P2Y12 (VN-P2Y12) assay, and a vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry assay—and their results were compared. Blood samples for pharmacokinetic assessments were collected at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours after dosing. Concentrations of the active metabolite of prasugrel were measured using a validated LC-MS/MS method.
Results: The study enrolled 18 Chinese subjects and 14 white subjects. Chinese subjects had a mean (SD) age of 31 (10) years and a mean body weight of 65.2 (8.9) kg; 83% were male. The corresponding values for white subjects were 30 (10) years, 77.2 (12.4) kg, and 86%. Thirty of the 32 enrolled subjects completed the study. Two Chinese men were withdrawn from the study, one due to a low platelet-rich plasma count after receipt of prasugrel 30 mg and the other due to mild, intermittent rectal bleeding after bowel movements that began ∼2 days after receipt of clopidogrel 300 mg. The mean IPA with prasugrel was significantly higher in Chinese than in white subjects at 0.5, 1, and 2 hours after dosing (
P < 0.05), but not at 4 or 24 hours. In Chinese subjects, mean maximal IPA (87%) occurred 1 hour after prasugrel dosing; in white subjects, mean maximal IPA (78%) occurred 2 hours after prasugrel dosing. In Chinese subjects, the mean IPA was significantly higher at all time points after administration of prasugrel 30 mg than after administration of clopidogrel 300 mg (
P <0.001). After administration of Clopidogrel 300 mg in Chinese subjects, mean maximal IPA (58%) occurred at 4 hours. The VN-P2Y12 and VASP phospho-rylation assays yielded results comparable to those obtained by LTA. Mean exposure to prasugrel's active metabolite was higher in Chinese than in white subjects (geometric least squares mean ratio for AUC
0−t = 1.47 (90% CI, 1.24–1.73). Both drugs were well tolerated.
Conclusions: In this study, platelet inhibition was significantly higher in Chinese than in white subjects up to 2 hours after a single 30-mg dose of prasugrel. Platelet inhibition was significantly higher in Chinese subjects at all time points after a 30-mg dose of prasugrel than after a 300-mg dose of clopidogrel. Both treatments were generally well tolerated. |
|---|---|
| AbstractList | Background: Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is 60 mg, earlier studies of prasugrel suggested that active-metabolite exposure and pharmacodynamic response may be higher in Asian subjects than in white subjects.
Objectives: This study compared the pharmacodynamic response to a single 30-mg dose of prasugrel in healthy Chinese and white subjects and the response to a single 30-mg dose of prasugrel and a single 300-mg dose of clopidogrel in healthy Chinese subjects. The pharmacokinetics and tolerability of both drugs were also assessed.
Methods: This was an open-label, single-dose study conducted in Singapore. Chinese subjects were randomly allocated to receive prasugrel 30 mg or clopidogrel 300 mg; after a 14-day washout period, they received the alternative drug. White subjects received only prasugrel 30 mg. Blood samples for pharmaco-dynamic assessments were collected before dosing and at 0.5, 1, 2, 4, and 24 hours after dosing. Three methods were used to measure inhibition of platelet aggregation (IPA)—traditional light transmission aggregometry (LTA), the Verify
Now P2Y12 (VN-P2Y12) assay, and a vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry assay—and their results were compared. Blood samples for pharmacokinetic assessments were collected at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours after dosing. Concentrations of the active metabolite of prasugrel were measured using a validated LC-MS/MS method.
Results: The study enrolled 18 Chinese subjects and 14 white subjects. Chinese subjects had a mean (SD) age of 31 (10) years and a mean body weight of 65.2 (8.9) kg; 83% were male. The corresponding values for white subjects were 30 (10) years, 77.2 (12.4) kg, and 86%. Thirty of the 32 enrolled subjects completed the study. Two Chinese men were withdrawn from the study, one due to a low platelet-rich plasma count after receipt of prasugrel 30 mg and the other due to mild, intermittent rectal bleeding after bowel movements that began ∼2 days after receipt of clopidogrel 300 mg. The mean IPA with prasugrel was significantly higher in Chinese than in white subjects at 0.5, 1, and 2 hours after dosing (
P < 0.05), but not at 4 or 24 hours. In Chinese subjects, mean maximal IPA (87%) occurred 1 hour after prasugrel dosing; in white subjects, mean maximal IPA (78%) occurred 2 hours after prasugrel dosing. In Chinese subjects, the mean IPA was significantly higher at all time points after administration of prasugrel 30 mg than after administration of clopidogrel 300 mg (
P <0.001). After administration of Clopidogrel 300 mg in Chinese subjects, mean maximal IPA (58%) occurred at 4 hours. The VN-P2Y12 and VASP phospho-rylation assays yielded results comparable to those obtained by LTA. Mean exposure to prasugrel's active metabolite was higher in Chinese than in white subjects (geometric least squares mean ratio for AUC
0−t = 1.47 (90% CI, 1.24–1.73). Both drugs were well tolerated.
Conclusions: In this study, platelet inhibition was significantly higher in Chinese than in white subjects up to 2 hours after a single 30-mg dose of prasugrel. Platelet inhibition was significantly higher in Chinese subjects at all time points after a 30-mg dose of prasugrel than after a 300-mg dose of clopidogrel. Both treatments were generally well tolerated. Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is 60 mg, earlier studies of prasugrel suggested that active-metabolite exposure and pharmacodynamic response may be higher in Asian subjects than in white subjects. This study compared the pharmacodynamic response to a single 30-mg dose of prasugrel in healthy Chinese and white subjects and the response to a single 30-mg dose of prasugrel and a single 300-mg dose of clopidogrel in healthy Chinese subjects. The pharmacokinetics and tolerability of both drugs were also assessed. This was an open-label, single-dose study conducted in Singapore. Chinese subjects were randomly allocated to receive prasugrel 30 mg or clopidogrel 300 mg; after a 14-day washout period, they received the alternative drug. White subjects received only prasugrel 30 mg. Blood samples for pharmaco-dynamic assessments were collected before dosing and at 0.5, 1, 2, 4, and 24 hours after dosing. Three methods were used to measure inhibition of platelet aggregation (IPA)-traditional light transmission aggregometry (LTA), the Verify Now P2Y12 (VN-P2Y12) assay, and a vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry assay-and their results were compared. Blood samples for pharmacokinetic assessments were collected at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours after dosing. Concentrations of the active metabolite of prasugrel were measured using a validated LC-MS/MS method. The study enrolled 18 Chinese subjects and 14 white subjects. Chinese subjects had a mean (SD) age of 31 (10) years and a mean body weight of 65.2 (8.9) kg; 83% were male. The corresponding values for white subjects were 30 (10) years, 77.2 (12.4) kg, and 86%. Thirty of the 32 enrolled subjects completed the study. Two Chinese men were withdrawn from the study, one due to a low platelet-rich plasma count after receipt of prasugrel 30 mg and the other due to mild, intermittent rectal bleeding after bowel movements that began approximately 2 days after receipt of clopidogrel 300 mg. The mean IPA with prasugrel was significantly higher in Chinese than in white subjects at 0.5, 1, and 2 hours after dosing (P < 0.05), but not at 4 or 24 hours. In Chinese subjects, mean maximal IPA (87%) occurred 1 hour after prasugrel dosing; in white subjects, mean maximal IPA (78%) occurred 2 hours after prasugrel dosing. In Chinese subjects, the mean IPA was significantly higher at all time points after administration of prasugrel 30 mg than after administration of clopidogrel 300 mg (P <0.001). After administration of Clopidogrel 300 mg in Chinese subjects, mean maximal IPA (58%) occurred at 4 hours. The VN-P2Y12 and VASP phosphorylation assays yielded results comparable to those obtained by LTA. Mean exposure to prasugrel's active metabolite was higher in Chinese than in white subjects (geometric least squares mean ratio for AUC(0-t) = 1.47 (90% CI, 1.24-1.73). Both drugs were well tolerated. In this study, platelet inhibition was significantly higher in Chinese than in white subjects up to 2 hours after a single 30-mg dose of prasugrel. Platelet inhibition was significantly higher in Chinese subjects at all time points after a 30-mg dose of prasugrel than after a 300-mg dose of clopidogrel. Both treatments were generally well tolerated. Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is 60 mg, earlier studies of prasugrel suggested that active-metabolite exposure and pharmacodynamic response may be higher in Asian subjects than in white subjects.BACKGROUNDPrasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is 60 mg, earlier studies of prasugrel suggested that active-metabolite exposure and pharmacodynamic response may be higher in Asian subjects than in white subjects.This study compared the pharmacodynamic response to a single 30-mg dose of prasugrel in healthy Chinese and white subjects and the response to a single 30-mg dose of prasugrel and a single 300-mg dose of clopidogrel in healthy Chinese subjects. The pharmacokinetics and tolerability of both drugs were also assessed.OBJECTIVESThis study compared the pharmacodynamic response to a single 30-mg dose of prasugrel in healthy Chinese and white subjects and the response to a single 30-mg dose of prasugrel and a single 300-mg dose of clopidogrel in healthy Chinese subjects. The pharmacokinetics and tolerability of both drugs were also assessed.This was an open-label, single-dose study conducted in Singapore. Chinese subjects were randomly allocated to receive prasugrel 30 mg or clopidogrel 300 mg; after a 14-day washout period, they received the alternative drug. White subjects received only prasugrel 30 mg. Blood samples for pharmaco-dynamic assessments were collected before dosing and at 0.5, 1, 2, 4, and 24 hours after dosing. Three methods were used to measure inhibition of platelet aggregation (IPA)-traditional light transmission aggregometry (LTA), the Verify Now P2Y12 (VN-P2Y12) assay, and a vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry assay-and their results were compared. Blood samples for pharmacokinetic assessments were collected at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours after dosing. Concentrations of the active metabolite of prasugrel were measured using a validated LC-MS/MS method.METHODSThis was an open-label, single-dose study conducted in Singapore. Chinese subjects were randomly allocated to receive prasugrel 30 mg or clopidogrel 300 mg; after a 14-day washout period, they received the alternative drug. White subjects received only prasugrel 30 mg. Blood samples for pharmaco-dynamic assessments were collected before dosing and at 0.5, 1, 2, 4, and 24 hours after dosing. Three methods were used to measure inhibition of platelet aggregation (IPA)-traditional light transmission aggregometry (LTA), the Verify Now P2Y12 (VN-P2Y12) assay, and a vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry assay-and their results were compared. Blood samples for pharmacokinetic assessments were collected at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours after dosing. Concentrations of the active metabolite of prasugrel were measured using a validated LC-MS/MS method.The study enrolled 18 Chinese subjects and 14 white subjects. Chinese subjects had a mean (SD) age of 31 (10) years and a mean body weight of 65.2 (8.9) kg; 83% were male. The corresponding values for white subjects were 30 (10) years, 77.2 (12.4) kg, and 86%. Thirty of the 32 enrolled subjects completed the study. Two Chinese men were withdrawn from the study, one due to a low platelet-rich plasma count after receipt of prasugrel 30 mg and the other due to mild, intermittent rectal bleeding after bowel movements that began approximately 2 days after receipt of clopidogrel 300 mg. The mean IPA with prasugrel was significantly higher in Chinese than in white subjects at 0.5, 1, and 2 hours after dosing (P < 0.05), but not at 4 or 24 hours. In Chinese subjects, mean maximal IPA (87%) occurred 1 hour after prasugrel dosing; in white subjects, mean maximal IPA (78%) occurred 2 hours after prasugrel dosing. In Chinese subjects, the mean IPA was significantly higher at all time points after administration of prasugrel 30 mg than after administration of clopidogrel 300 mg (P <0.001). After administration of Clopidogrel 300 mg in Chinese subjects, mean maximal IPA (58%) occurred at 4 hours. The VN-P2Y12 and VASP phosphorylation assays yielded results comparable to those obtained by LTA. Mean exposure to prasugrel's active metabolite was higher in Chinese than in white subjects (geometric least squares mean ratio for AUC(0-t) = 1.47 (90% CI, 1.24-1.73). Both drugs were well tolerated.RESULTSThe study enrolled 18 Chinese subjects and 14 white subjects. Chinese subjects had a mean (SD) age of 31 (10) years and a mean body weight of 65.2 (8.9) kg; 83% were male. The corresponding values for white subjects were 30 (10) years, 77.2 (12.4) kg, and 86%. Thirty of the 32 enrolled subjects completed the study. Two Chinese men were withdrawn from the study, one due to a low platelet-rich plasma count after receipt of prasugrel 30 mg and the other due to mild, intermittent rectal bleeding after bowel movements that began approximately 2 days after receipt of clopidogrel 300 mg. The mean IPA with prasugrel was significantly higher in Chinese than in white subjects at 0.5, 1, and 2 hours after dosing (P < 0.05), but not at 4 or 24 hours. In Chinese subjects, mean maximal IPA (87%) occurred 1 hour after prasugrel dosing; in white subjects, mean maximal IPA (78%) occurred 2 hours after prasugrel dosing. In Chinese subjects, the mean IPA was significantly higher at all time points after administration of prasugrel 30 mg than after administration of clopidogrel 300 mg (P <0.001). After administration of Clopidogrel 300 mg in Chinese subjects, mean maximal IPA (58%) occurred at 4 hours. The VN-P2Y12 and VASP phosphorylation assays yielded results comparable to those obtained by LTA. Mean exposure to prasugrel's active metabolite was higher in Chinese than in white subjects (geometric least squares mean ratio for AUC(0-t) = 1.47 (90% CI, 1.24-1.73). Both drugs were well tolerated.In this study, platelet inhibition was significantly higher in Chinese than in white subjects up to 2 hours after a single 30-mg dose of prasugrel. Platelet inhibition was significantly higher in Chinese subjects at all time points after a 30-mg dose of prasugrel than after a 300-mg dose of clopidogrel. Both treatments were generally well tolerated.CONCLUSIONSIn this study, platelet inhibition was significantly higher in Chinese than in white subjects up to 2 hours after a single 30-mg dose of prasugrel. Platelet inhibition was significantly higher in Chinese subjects at all time points after a 30-mg dose of prasugrel than after a 300-mg dose of clopidogrel. Both treatments were generally well tolerated. Background_ Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is 60 mg, earlier studies of prasugrel suggested that active-metabolite exposure and pharmacodynamic response may be higher in Asian subjects than in white subjects. Objectives_ This study compared the pharmacodynamic response to a single 30-mg dose of prasugrel in healthy Chinese and white subjects and the response to a single 30-mg dose of prasugrel and a single 300-mg dose of clopidogrel in healthy Chinese subjects. The pharmacokinetics and tolerability of both drugs were also assessed. Methods_ This was an open-label, single-dose study conducted in Singapore. Chinese subjects were randomly allocated to receive prasugrel 30 mg or clopidogrel 300 mg; after a 14-day washout period, they received the alternative drug. White subjects received only prasugrel 30 mg. Blood samples for pharmaco-dynamic assessments were collected before dosing and at 0.5, 1, 2, 4, and 24 hours after dosing. Three methods were used to measure inhibition of platelet aggregation (IPA)--traditional light transmission aggregometry (LTA), the Verify Now P2Y12 (VN-P2Y12) assay, and a vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry assay--and their results were compared. Blood samples for pharmacokinetic assessments were collected at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours after dosing. Concentrations of the active metabolite of prasugrel were measured using a validated LC-MS/MS method. Results_ The study enrolled 18 Chinese subjects and 14 white subjects. Chinese subjects had a mean (SD) age of 31 (10) years and a mean body weight of 65.2 (8.9) kg; 83% were male. The corresponding values for white subjects were 30 (10) years, 77.2 (12.4) kg, and 86%. Thirty of the 32 enrolled subjects completed the study. Two Chinese men were withdrawn from the study, one due to a low platelet-rich plasma count after receipt of prasugrel 30 mg and the other due to mild, intermittent rectal bleeding after bowel movements that began ∼2 days after receipt of clopidogrel 300 mg. The mean IPA with prasugrel was significantly higher in Chinese than in white subjects at 0.5, 1, and 2 hours after dosing (P < 0.05), but not at 4 or 24 hours. In Chinese subjects, mean maximal IPA (87%) occurred 1 hour after prasugrel dosing; in white subjects, mean maximal IPA (78%) occurred 2 hours after prasugrel dosing. In Chinese subjects, the mean IPA was significantly higher at all time points after administration of prasugrel 30 mg than after administration of clopidogrel 300 mg (P <0.001). After administration of Clopidogrel 300 mg in Chinese subjects, mean maximal IPA (58%) occurred at 4 hours. The VN-P2Y12 and VASP phospho-rylation assays yielded results comparable to those obtained by LTA. Mean exposure to prasugrel's active metabolite was higher in Chinese than in white subjects (geometric least squares mean ratio for AUC0-t = 1.47 (90% CI, 1.24-1.73). Both drugs were well tolerated. Conclusions_ In this study, platelet inhibition was significantly higher in Chinese than in white subjects up to 2 hours after a single 30-mg dose of prasugrel. Platelet inhibition was significantly higher in Chinese subjects at all time points after a 30-mg dose of prasugrel than after a 300-mg dose of clopidogrel. Both treatments were generally well tolerated. Abstract Background: Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is 60 mg, earlier studies of prasugrel suggested that active-metabolite exposure and pharmacodynamic response may be higher in Asian subjects than in white subjects. Objectives: This study compared the pharmacodynamic response to a single 30-mg dose of prasugrel in healthy Chinese and white subjects and the response to a single 30-mg dose of prasugrel and a single 300-mg dose of clopidogrel in healthy Chinese subjects. The pharmacokinetics and tolerability of both drugs were also assessed. Methods: This was an open-label, single-dose study conducted in Singapore. Chinese subjects were randomly allocated to receive prasugrel 30 mg or clopidogrel 300 mg; after a 14-day washout period, they received the alternative drug. White subjects received only prasugrel 30 mg. Blood samples for pharmaco-dynamic assessments were collected before dosing and at 0.5, 1, 2, 4, and 24 hours after dosing. Three methods were used to measure inhibition of platelet aggregation (IPA)—traditional light transmission aggregometry (LTA), the Verify Now P2Y12 (VN-P2Y12) assay, and a vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry assay—and their results were compared. Blood samples for pharmacokinetic assessments were collected at 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, and 24 hours after dosing. Concentrations of the active metabolite of prasugrel were measured using a validated LC-MS/MS method. Results: The study enrolled 18 Chinese subjects and 14 white subjects. Chinese subjects had a mean (SD) age of 31 (10) years and a mean body weight of 65.2 (8.9) kg; 83% were male. The corresponding values for white subjects were 30 (10) years, 77.2 (12.4) kg, and 86%. Thirty of the 32 enrolled subjects completed the study. Two Chinese men were withdrawn from the study, one due to a low platelet-rich plasma count after receipt of prasugrel 30 mg and the other due to mild, intermittent rectal bleeding after bowel movements that began ∼2 days after receipt of clopidogrel 300 mg. The mean IPA with prasugrel was significantly higher in Chinese than in white subjects at 0.5, 1, and 2 hours after dosing ( P < 0.05), but not at 4 or 24 hours. In Chinese subjects, mean maximal IPA (87%) occurred 1 hour after prasugrel dosing; in white subjects, mean maximal IPA (78%) occurred 2 hours after prasugrel dosing. In Chinese subjects, the mean IPA was significantly higher at all time points after administration of prasugrel 30 mg than after administration of clopidogrel 300 mg ( P <0.001). After administration of Clopidogrel 300 mg in Chinese subjects, mean maximal IPA (58%) occurred at 4 hours. The VN-P2Y12 and VASP phospho-rylation assays yielded results comparable to those obtained by LTA. Mean exposure to prasugrel's active metabolite was higher in Chinese than in white subjects (geometric least squares mean ratio for AUC0−t = 1.47 (90% CI, 1.24–1.73). Both drugs were well tolerated. Conclusions: In this study, platelet inhibition was significantly higher in Chinese than in white subjects up to 2 hours after a single 30-mg dose of prasugrel. Platelet inhibition was significantly higher in Chinese subjects at all time points after a 30-mg dose of prasugrel than after a 300-mg dose of clopidogrel. Both treatments were generally well tolerated. |
| Author | Yuen, Eunice Ni, Lan Payne, Christopher D. Winters, Kenneth J. Natanegara, Fanni Richard Lachno, D. Li, Ying G. Salazar, Daniel E. Small, David S. Tomlin, Molly Jakubowski, Joseph A. Kelly, Ronan Farid, Nagy A. Kothare, Prajakti Teng Loh, Mei |
| Author_xml | – sequence: 1 givenname: David S. surname: Small fullname: Small, David S. email: dsmall@lilly.com organization: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana – sequence: 2 givenname: Christopher D. surname: Payne fullname: Payne, Christopher D. organization: Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom – sequence: 3 givenname: Prajakti surname: Kothare fullname: Kothare, Prajakti organization: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana – sequence: 4 givenname: Eunice surname: Yuen fullname: Yuen, Eunice organization: Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom – sequence: 5 givenname: Fanni surname: Natanegara fullname: Natanegara, Fanni organization: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana – sequence: 6 givenname: Mei surname: Teng Loh fullname: Teng Loh, Mei organization: Lilly-NUS Centre for Clinical Pharmacology, Singapore – sequence: 7 givenname: Joseph A. surname: Jakubowski fullname: Jakubowski, Joseph A. organization: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana – sequence: 8 givenname: D. surname: Richard Lachno fullname: Richard Lachno, D. organization: Lilly Research Laboratories, Eli Lilly and Company, Windlesham, Surrey, United Kingdom – sequence: 9 givenname: Ying G. surname: Li fullname: Li, Ying G. organization: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana – sequence: 10 givenname: Kenneth J. surname: Winters fullname: Winters, Kenneth J. organization: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana – sequence: 11 givenname: Nagy A. surname: Farid fullname: Farid, Nagy A. organization: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana – sequence: 12 givenname: Lan surname: Ni fullname: Ni, Lan organization: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana – sequence: 13 givenname: Daniel E. surname: Salazar fullname: Salazar, Daniel E. organization: Daiichi Sankyo, Inc., Parsippany, New Jersey – sequence: 14 givenname: Molly surname: Tomlin fullname: Tomlin, Molly organization: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana – sequence: 15 givenname: Ronan surname: Kelly fullname: Kelly, Ronan organization: Lilly-NUS Centre for Clinical Pharmacology, Singapore |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22575739$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20206794$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkm2L1DAUhYusuLOrf0ELIn7qeJO-CyrD4hssKKjgt5BJb6eZTZOapCvzX_yxpjN1FwaE-RRy8pyT5HIuojNtNEbRMwJLAqR4tV0KJbXv0PIlhaACXQLJH0QLUpV1Qkj28yxaAMnqhNakOo8unNsCQFrn9FF0ToFCUdbZIvrzteO258I0O817KVzMdRMPs3gjNfpJNG3spN4ojBvjcL8fLHfjxqKKU4j7zd4nlBlkY2Z1L0sdd8iV73ax6EKcwz35u5Me41ujRu0RrXsdr3RsBtSJ4uvg9lZy9Th62HLl8Mm8XkY_Prz_fvUpuf7y8fPV6joRBeQ-4VCStuIZzRuRhf9nAHxdZFgJAmlTZetCtGWBOamLvE5JDWkVTnFNoMlpMKSX0ctD7mDNrxGdZ710ApXiGs3oWJmmBHJKy0A-PyK3ZrQ6PI6Fu1JSQEpooJ7O1LjusWGDlT23O_Zv7AF4MQPcCa5ay7WQ7p6jeZmXaR248sAJa5yz2N4hBNhUBLZld0VgUxEYUBaKEJxvjpxCeu6l0d5yqU7wrw5-DHO_lWiZExK1wEZaFJ41Rp6Q8fYoY-Jk-PAN7tDdT465YGDfprpObSWhqFAU05je_T_gpCf8BVto_fs |
| CitedBy_id | crossref_primary_10_1007_s00228_012_1329_z crossref_primary_10_1016_j_jep_2013_12_018 crossref_primary_10_1016_j_gheart_2014_08_001 crossref_primary_10_1097_FJC_0000000000001225 crossref_primary_10_1517_14656566_2012_704909 crossref_primary_10_1016_j_clinbiochem_2014_03_005 crossref_primary_10_2147_IJGM_S307404 crossref_primary_10_1186_1745_6215_14_62 crossref_primary_10_3109_09537104_2014_959913 crossref_primary_10_1097_FJC_0b013e3181dd0ec2 crossref_primary_10_1007_s11239_012_0782_y crossref_primary_10_1177_0091270010367429 crossref_primary_10_1038_aps_2012_120 crossref_primary_10_1016_j_thromres_2011_11_023 crossref_primary_10_1517_17425255_2013_749238 crossref_primary_10_1016_j_amjcard_2015_05_026 crossref_primary_10_1016_j_jjcc_2011_03_002 crossref_primary_10_1097_FJC_0b013e318290d9e1 crossref_primary_10_2217_cer_2017_0074 crossref_primary_10_1111_jth_13197 crossref_primary_10_1155_2015_892470 crossref_primary_10_2478_fzm_2022_0004 crossref_primary_10_1016_j_ahj_2010_10_017 crossref_primary_10_1016_j_clinthera_2011_04_007 crossref_primary_10_1016_j_ijcard_2016_06_063 crossref_primary_10_1093_neuros_nyy341 crossref_primary_10_1007_s40262_020_00864_4 crossref_primary_10_1016_j_dmpk_2016_03_006 crossref_primary_10_1016_j_thromres_2018_11_013 crossref_primary_10_1159_000478000 crossref_primary_10_3390_pharmaceutics14050915 crossref_primary_10_1038_nrcardio_2014_104 crossref_primary_10_2165_11537820_000000000_00000 crossref_primary_10_1016_j_jchromb_2011_11_029 crossref_primary_10_1111_j_1755_5922_2011_00263_x crossref_primary_10_1097_MD_0000000000018683 crossref_primary_10_1038_srep31838 crossref_primary_10_1080_10826076_2011_582209 crossref_primary_10_1002_cpdd_308 crossref_primary_10_1016_j_ijcard_2016_08_027 |
| Cites_doi | 10.1592/phco.28.12.1483 10.1016/j.jpba.2008.08.020 10.1056/NEJMoa0706482 10.1093/eurheartj/ehi877 10.1097/FJC.0b013e318031301b 10.1160/TH07-09-0575 10.1177/0091270008315310 10.1093/eurheartj/ehm545 10.1007/s10928-008-9103-7 10.1160/TH07-09-0555 10.1002/rcm.2813 10.1007/s00228-009-0737-1 10.1111/j.1527-3466.2007.00027.x 10.1161/CIRCULATIONAHA.107.740324 10.1146/annurev.pharmtox.46.120604.141207 10.2165/11315780-000000000-00000 |
| ContentType | Journal Article |
| Copyright | 2010 2015 INIST-CNRS Copyright 2010. Published by EM Inc USA. Copyright Elsevier Limited Feb 2010 |
| Copyright_xml | – notice: 2010 – notice: 2015 INIST-CNRS – notice: Copyright 2010. Published by EM Inc USA. – notice: Copyright Elsevier Limited Feb 2010 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88C 88E 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O M7N MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1016/j.clinthera.2010.02.015 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Research Library Prep |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-114X |
| EndPage | 379 |
| ExternalDocumentID | 2734245501 20206794 22575739 10_1016_j_clinthera_2010_02_015 S0149291810000664 1_s2_0_S0149291810000664 |
| Genre | Randomized Controlled Trial Journal Article Comparative Study |
| GeographicLocations | Asia China Singapore United Kingdom--UK United States--US Indianapolis Indiana |
| GeographicLocations_xml | – name: Singapore – name: China – name: United Kingdom--UK – name: United States--US – name: Indianapolis Indiana |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29B 4.4 457 4G. 53G 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABUWG ABWVN ABXDB ABZDS ACDAQ ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HMCUK HVGLF HZ~ H~9 IHE J1W KOM M0T M1P M2O M41 MO0 N9A NAPCQ O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q38 R2- ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSZ SV3 T5K UHS UKHRP WH7 WOW XOL Z5R ZGI ZXP ~G- 0SF 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW NCXOZ RIG AAIAV AATCM ABLVK ABYKQ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7XB 8FK K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c605t-a071f8a425dc4187400ab64e8c103d84b6cf76e51965931903864eeb10d524183 |
| IEDL.DBID | 7X7 |
| ISSN | 0149-2918 1879-114X |
| IngestDate | Sun Aug 24 03:44:25 EDT 2025 Sat Jul 26 03:08:57 EDT 2025 Mon Jul 21 06:04:05 EDT 2025 Mon Jul 21 09:14:43 EDT 2025 Thu Apr 24 23:05:00 EDT 2025 Tue Jul 01 04:21:22 EDT 2025 Fri Feb 23 02:23:23 EST 2024 Sun Feb 23 10:18:55 EST 2025 Tue Aug 26 16:34:15 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | clopidogrel prasugrel East Asian population platelet aggregation Asiatic Volunteer Pharmacotherapy Aggregation Hemostasis Race Antithrombotic agent Clinical trial Human Drug Pharmacodynamics Healthy subject Single dose Ethnic group Biological activity Antiplatelet agent Prasugrel Platelet Treatment Platelet function Clopidogrel Thienopyridine derivative Caucasoid Pharmacokinetics |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright 2010. Published by EM Inc USA. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c605t-a071f8a425dc4187400ab64e8c103d84b6cf76e51965931903864eeb10d524183 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Undefined-1 ObjectType-Feature-3 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| PMID | 20206794 |
| PQID | 1033160312 |
| PQPubID | 1226358 |
| PageCount | 15 |
| ParticipantIDs | proquest_miscellaneous_733105227 proquest_journals_1033160312 pubmed_primary_20206794 pascalfrancis_primary_22575739 crossref_primary_10_1016_j_clinthera_2010_02_015 crossref_citationtrail_10_1016_j_clinthera_2010_02_015 elsevier_sciencedirect_doi_10_1016_j_clinthera_2010_02_015 elsevier_clinicalkeyesjournals_1_s2_0_S0149291810000664 elsevier_clinicalkey_doi_10_1016_j_clinthera_2010_02_015 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-02-01 |
| PublicationDateYYYYMMDD | 2010-02-01 |
| PublicationDate_xml | – month: 02 year: 2010 text: 2010-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Bridgewater, NJ |
| PublicationPlace_xml | – name: Bridgewater, NJ – name: United States – name: Bridgewater |
| PublicationTitle | Clinical therapeutics |
| PublicationTitleAlternate | Clin Ther |
| PublicationYear | 2010 |
| Publisher | EM Inc USA Elsevier Elsevier Limited |
| Publisher_xml | – name: EM Inc USA – name: Elsevier – name: Elsevier Limited |
| References | Brandt, Payne, Wiviott (bib5) 2007; 153 Small, Kothare, Yuen (bib9) 2010; 66 Wiviott, Trenk, Frelinger (bib7) 2007; 116 Takahashi, Pang, Kawabata (bib19) 2008; 48 Wallentin, Varenhorst, James (bib17) 2008; 29 Farid, McIntosh, Garofolo (bib18) 2007; 21 Gachet (bib1) 2006; 46 Small, Wrishko, Ernest (bib16) July 27–August 1, 2008 bib21 Salazar, Ernest, Wrishko (bib20) 2008; 118 Jakubowski, Winters, Naganuma, Wallentin (bib4) 2007; 25 Small, Wrishko, Ernest (bib15) 2009; 26 Ernest, Small, Rohatagi (bib3) 2008; 35 Jernberg, Payne, Winters (bib6) 2006; 27 Jakubowski, Payne, Li (bib10) 2008; 99 Wiviott, Braunwald, McCabe (bib8) 2007; 357 Jakubowski, Payne, Weerakkody (bib12) 2007; 49 Jakubowski, Payne, Li (bib11) 2008; 99 bib2 Farid, Small, Payne (bib13) 2008; 28 Small, Farid, Payne (bib14) 2008; 48 Brandt (10.1016/j.clinthera.2010.02.015_bib5) 2007; 153 Jernberg (10.1016/j.clinthera.2010.02.015_bib6) 2006; 27 Jakubowski (10.1016/j.clinthera.2010.02.015_bib10) 2008; 99 Jakubowski (10.1016/j.clinthera.2010.02.015_bib11) 2008; 99 Farid (10.1016/j.clinthera.2010.02.015_bib18) 2007; 21 Wiviott (10.1016/j.clinthera.2010.02.015_bib8) 2007; 357 Farid (10.1016/j.clinthera.2010.02.015_bib13) 2008; 28 Small (10.1016/j.clinthera.2010.02.015_bib14) 2008; 48 Small (10.1016/j.clinthera.2010.02.015_bib16) 2008 Jakubowski (10.1016/j.clinthera.2010.02.015_bib12) 2007; 49 Takahashi (10.1016/j.clinthera.2010.02.015_bib19) 2008; 48 Gachet (10.1016/j.clinthera.2010.02.015_bib1) 2006; 46 Salazar (10.1016/j.clinthera.2010.02.015_bib20) 2008; 118 Wallentin (10.1016/j.clinthera.2010.02.015_bib17) 2008; 29 Jakubowski (10.1016/j.clinthera.2010.02.015_bib4) 2007; 25 Ernest (10.1016/j.clinthera.2010.02.015_bib3) 2008; 35 Wiviott (10.1016/j.clinthera.2010.02.015_bib7) 2007; 116 Small (10.1016/j.clinthera.2010.02.015_bib15) 2009; 26 Small (10.1016/j.clinthera.2010.02.015_bib9) 2010; 66 |
| References_xml | – ident: bib2 article-title: Summary of product characteristics. Efient 5mg & 10mg film-coated tablets (Eli Lilly and Company Limited/Daiichi Sankyo UK Limited) – volume: 99 start-page: 215 year: 2008 end-page: 222 ident: bib10 article-title: A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry publication-title: Thromb Haemost. – volume: 357 start-page: 2001 year: 2007 end-page: 2015 ident: bib8 article-title: Prasugrel versus clopidogrel in patients with acute coronary syndromes publication-title: N Engl J Med. – volume: 25 start-page: 357 year: 2007 end-page: 374 ident: bib4 article-title: A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile publication-title: Cardiovasc Drug Rev. – volume: 66 start-page: 127 year: 2010 end-page: 135 ident: bib9 article-title: The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects publication-title: Eur J Clin Pharmacol. – volume: 118 start-page: S815 year: 2008 ident: bib20 article-title: Relationship between exposure to the prasugrel active metabolite with TIMI major/minor bleeding in TRITON-TIMI 38 publication-title: Circulation – volume: 153 start-page: e9 year: 2007 end-page: e16 ident: bib5 article-title: A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation publication-title: Am Heart J. – volume: 29 start-page: 21 year: 2008 end-page: 30 ident: bib17 article-title: Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease publication-title: Eur Heart J. – volume: 28 start-page: 1483 year: 2008 end-page: 1494 ident: bib13 article-title: Effect of atorvastatin on the pharmacokinetics and pharmaco-dynamics of prasugrel and clopidogrel in healthy subjects publication-title: Pharmacotherapy. – volume: 48 start-page: 1219 year: 2008 end-page: 1224 ident: bib19 article-title: Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS publication-title: J Pharm Biomed Anal. – volume: 49 start-page: 167 year: 2007 end-page: 173 ident: bib12 article-title: Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects publication-title: J Cardiovasc Pharmacol. – ident: bib21 article-title: ClinicalTrials.gov. A comparison of antiplatelet therapies in Asian subjects with acute coronary syndrome – year: July 27–August 1, 2008 ident: bib16 article-title: Comparison of the pharmacokinetics and pharmacodynamics of prasugrel in subjects with end-stage renal disease and healthy subjects publication-title: Presented at: Ninth World Conference on Clinical Pharmacology and Therapeutics – volume: 35 start-page: 593 year: 2008 end-page: 618 ident: bib3 article-title: Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease publication-title: J Pharmacokinet Pharmacodyn. – volume: 99 start-page: 409 year: 2008 end-page: 415 ident: bib11 article-title: The use ofthe Verify Now P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration publication-title: Thromb Haemost. – volume: 26 start-page: 781 year: 2009 end-page: 790 ident: bib15 article-title: Effect of age on the pharma-cokinetics and pharmacodynamics of prasugrel during multiple dosing: An open-label, single-sequence, clinical trial publication-title: Drugs Aging. – volume: 46 start-page: 277 year: 2006 end-page: 300 ident: bib1 article-title: Regulation of platelet functions by P2 receptors publication-title: Annu Rev Pharmacol Toxicol. – volume: 21 start-page: 169 year: 2007 end-page: 179 ident: bib18 article-title: Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry publication-title: Rapid Commun Mass Spectrom. – volume: 27 start-page: 1166 year: 2006 end-page: 1173 ident: bib6 article-title: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirintreated patients with stable coronary artery disease publication-title: Eur Heart J. – volume: 116 start-page: 2923 year: 2007 end-page: 2932 ident: bib7 article-title: Prasugrel compared with high loading- and maintenancedose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial publication-title: Circulation. – volume: 48 start-page: 475 year: 2008 end-page: 484 ident: bib14 article-title: Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel publication-title: J Clin Pharmacol. – volume: 28 start-page: 1483 year: 2008 ident: 10.1016/j.clinthera.2010.02.015_bib13 article-title: Effect of atorvastatin on the pharmacokinetics and pharmaco-dynamics of prasugrel and clopidogrel in healthy subjects publication-title: Pharmacotherapy. doi: 10.1592/phco.28.12.1483 – volume: 48 start-page: 1219 year: 2008 ident: 10.1016/j.clinthera.2010.02.015_bib19 article-title: Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS publication-title: J Pharm Biomed Anal. doi: 10.1016/j.jpba.2008.08.020 – volume: 357 start-page: 2001 year: 2007 ident: 10.1016/j.clinthera.2010.02.015_bib8 article-title: Prasugrel versus clopidogrel in patients with acute coronary syndromes publication-title: N Engl J Med. doi: 10.1056/NEJMoa0706482 – volume: 27 start-page: 1166 year: 2006 ident: 10.1016/j.clinthera.2010.02.015_bib6 article-title: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirintreated patients with stable coronary artery disease publication-title: Eur Heart J. doi: 10.1093/eurheartj/ehi877 – volume: 49 start-page: 167 year: 2007 ident: 10.1016/j.clinthera.2010.02.015_bib12 article-title: Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects publication-title: J Cardiovasc Pharmacol. doi: 10.1097/FJC.0b013e318031301b – volume: 118 start-page: S815 issue: Suppl 2 year: 2008 ident: 10.1016/j.clinthera.2010.02.015_bib20 article-title: Relationship between exposure to the prasugrel active metabolite with TIMI major/minor bleeding in TRITON-TIMI 38 publication-title: Circulation – volume: 99 start-page: 409 year: 2008 ident: 10.1016/j.clinthera.2010.02.015_bib11 article-title: The use ofthe Verify Now P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration publication-title: Thromb Haemost. doi: 10.1160/TH07-09-0575 – volume: 48 start-page: 475 year: 2008 ident: 10.1016/j.clinthera.2010.02.015_bib14 article-title: Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel publication-title: J Clin Pharmacol. doi: 10.1177/0091270008315310 – volume: 29 start-page: 21 year: 2008 ident: 10.1016/j.clinthera.2010.02.015_bib17 article-title: Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease publication-title: Eur Heart J. doi: 10.1093/eurheartj/ehm545 – volume: 35 start-page: 593 year: 2008 ident: 10.1016/j.clinthera.2010.02.015_bib3 article-title: Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease publication-title: J Pharmacokinet Pharmacodyn. doi: 10.1007/s10928-008-9103-7 – volume: 99 start-page: 215 year: 2008 ident: 10.1016/j.clinthera.2010.02.015_bib10 article-title: A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry publication-title: Thromb Haemost. doi: 10.1160/TH07-09-0555 – volume: 21 start-page: 169 year: 2007 ident: 10.1016/j.clinthera.2010.02.015_bib18 article-title: Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry publication-title: Rapid Commun Mass Spectrom. doi: 10.1002/rcm.2813 – volume: 66 start-page: 127 year: 2010 ident: 10.1016/j.clinthera.2010.02.015_bib9 article-title: The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects publication-title: Eur J Clin Pharmacol. doi: 10.1007/s00228-009-0737-1 – volume: 25 start-page: 357 year: 2007 ident: 10.1016/j.clinthera.2010.02.015_bib4 article-title: A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile publication-title: Cardiovasc Drug Rev. doi: 10.1111/j.1527-3466.2007.00027.x – volume: 153 start-page: e9 issue: 66 year: 2007 ident: 10.1016/j.clinthera.2010.02.015_bib5 article-title: A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation publication-title: Am Heart J. – volume: 116 start-page: 2923 year: 2007 ident: 10.1016/j.clinthera.2010.02.015_bib7 article-title: Prasugrel compared with high loading- and maintenancedose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial publication-title: Circulation. doi: 10.1161/CIRCULATIONAHA.107.740324 – volume: 46 start-page: 277 year: 2006 ident: 10.1016/j.clinthera.2010.02.015_bib1 article-title: Regulation of platelet functions by P2 receptors publication-title: Annu Rev Pharmacol Toxicol. doi: 10.1146/annurev.pharmtox.46.120604.141207 – volume: 26 start-page: 781 year: 2009 ident: 10.1016/j.clinthera.2010.02.015_bib15 article-title: Effect of age on the pharma-cokinetics and pharmacodynamics of prasugrel during multiple dosing: An open-label, single-sequence, clinical trial publication-title: Drugs Aging. doi: 10.2165/11315780-000000000-00000 – year: 2008 ident: 10.1016/j.clinthera.2010.02.015_bib16 article-title: Comparison of the pharmacokinetics and pharmacodynamics of prasugrel in subjects with end-stage renal disease and healthy subjects |
| SSID | ssj0003952 |
| Score | 2.143289 |
| Snippet | Background: Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute... Abstract Background: Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with... Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary... Background_ Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 365 |
| SubjectTerms | Administration, Oral Adult Asian Continental Ancestry Group Aspirin Biological and medical sciences Blood platelets Blood Platelets - drug effects Blood Platelets - metabolism Blood. Blood coagulation. Reticuloendothelial system Cardiovascular disease Cell Adhesion Molecules - blood China - ethnology clopidogrel Coronary vessels Drug therapy East Asian population European Continental Ancestry Group Female Flow Cytometry Humans Internal Medicine Laboratories Male Medical Education Medical sciences Microfilament Proteins - blood Middle Aged Pharmacodynamics Pharmacokinetics Pharmacology. Drug treatments Phosphoproteins - blood Piperazines - administration & dosage Piperazines - adverse effects Piperazines - pharmacokinetics platelet aggregation Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - pharmacokinetics Platelet Function Tests prasugrel Prasugrel Hydrochloride Purinergic P2 Receptor Antagonists Receptors, Purinergic P2 - blood Receptors, Purinergic P2Y12 Singapore - epidemiology Thiophenes - administration & dosage Thiophenes - adverse effects Thiophenes - pharmacokinetics Ticlopidine - administration & dosage Ticlopidine - adverse effects Ticlopidine - analogs & derivatives Ticlopidine - pharmacokinetics Vein & artery diseases Young Adult |
| SummonAdditionalLinks | – databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] dbid: AIKHN link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED-6FMagjK378tYVPYw-1Ysc-UPpWygr2cZKH1rom5BleaTLHFMnlPwv-2N3J8sOYR0d7NGyzpat0-_O1t39AD7IIrWGflRFWZSHcZTrUFuTh6mItNGlkdK6ANnzdHoVf7lOrnfgtMuFobBKj_0tpju09i1D_zaH9Ww2pLAktO1ooRzmpvEj2B2JcSoHsDv5_HV63gOyGDviHeofksBWmBclILpUJx_mNfrIiSL3fiO1V-sGX13Zcl783Sl1xunsGTz1XiWbtAN_Dju22ofH3_y--T4cXbQVqtfH7HKTcNUcsyN2saldvX4Bv7rDomWqb5iuClb7xh94MZJji5LRP4a5ZcWise64vtXNCj_e50xw9vO7kzOUjlUsfKtrnlWsTb1cM4ritI11Pe9oN4MRVOJEo0d6wiYVI2avELUUpR25yEu4Ovt0eToNPYFDaPAraRlq9F9KqREWChM78j-u8zS20kRcFDLOU1NmqU1cVUPEAi4knkXrwYsEPQspXsGgWlT2DTB0VATt8GppyjjNUfUkTxCbNDqgRsZFAGk3Y8r46uZEsjFXXRjbjeqnWtFUKz5SONUB8F6wbgt8PCwiO5VQXf4qIq5CI_SwaHafqG08cjQqUg32VH9odwAnveTWAvm32x5uaW7_pIjmWZKJcQAHnSqrzVC4EI6FfBQA608j_NCekq7sYtUoovzk6MNnAbxuV8Dm2pyoAcbx2_8Z-Tt40sZrUADRAQyWtyv7Ht3AZX7ol_lv-6hcXw priority: 102 providerName: Elsevier |
| Title | Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0149291810000664 https://www.clinicalkey.es/playcontent/1-s2.0-S0149291810000664 https://dx.doi.org/10.1016/j.clinthera.2010.02.015 https://www.ncbi.nlm.nih.gov/pubmed/20206794 https://www.proquest.com/docview/1033160312 https://www.proquest.com/docview/733105227 |
| Volume | 32 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-xTUJICMH4CozKD2hPy-Q0X-5eUEGbCoiqQpvUN8txnAkoSZlbob7wl_DHcuc4qSYNxlMVJ-e0vfP5zvfxA3gtysxoOqiK8qgIk6hQoTK6CLM4UlpVWgjjEmSn2eQi-TBP5_7Azfq0yk4nOkVdNprOyHF1x7GDRB6-Wf4ICTWKoqseQmMH9qh1GTlf-bx3uHg8cog75AWEw1EkruV3UeWhq3Hy-V3DY07YuDfvTveXyuJ_VrVgF3-3Rt2udPYQHnhzko1b_j-CO6beh7uffMB8Hw5nbWvqzRE731Za2SN2yGbbptWbx_C7uyxbiHrLVF2ypR_8hpMRHWsqRocLC8PKxhp3vbxSdo1e-4LFnH2_dHSa6rDKxo-64S81a2suN4zSN4017smfFMZgpCORw2iKnrBxzQjSK0TxRGqHKvIELs5Oz99NQo_cEGp0j1ahQsOlEgr1QakTh_rHVZElRmhkYymSItNVnpnUtTNEJcBjgXdx2-BliiaFiJ_Cbt3U5jkwtFBiCu0qoaskK1DmBE9RKSm0PLVIygCyjmNS-7bmhK6xkF3-2lfZs1oSqyUfSmR1ALwnXLadPW4nEZ1IyK5wFVWtxN3ndtL8JlJjvcqwMpIWn3TZdiMSVhd4ybIkgJOe0ltFrbXzf68dXJPc_peiGs_TPB4FcNCJstx-lX6tBcD626h3KJikatOsrSSsT47Gex7As3YFbOfmhAkwSl78e-6XcK9NxaDcoAPYXV2tzSu08FbFAHaOf0UDt5gHsDd-_3Eyxc-3p9PZ5z-uo1Qh |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIkElhKC8AqX4AD01yHls4lRCqAKqLX2oh620N-M4TkXZJstmV1X-C7-B38iM81hVKpRLj3E8zq5mPDP2PD6AtyKLjKaLKi_2Ujf0UuUqo1M3CjylVa6FMDZB9jganoZfx4PxCvzuamEorbLTiVZRZ6WmO3Lc3UFgIZH9j9OfLqFGUXS1g9BoxOLA1Jd4ZKs-7H9G_r7z_b0vo09Dt0UVcDW67nNXoVHNhUJZzXRoEem4SqPQCI2fyESYRjqPIzOwrfZQQHkg8C2qNJ4N0NyJANe9A3fR8HJKIYzH_QGPB4lF-KFTh-snnriST0aVjramqs0n899zwuK93ho-mKoKeZQ34Bp_936tFdx7BA9b95XtNvL2GFZMsQ73jtoA_TpsnTStsOttNlpWdlXbbIudLJtk10_gV_eY1YW6wClMFRmbtoM_cDGiY2XO6DJjYlhWVsY-T2eqWpzNzIQFnF2cWTpNdV9Z2Y7a4e8Fa2o8a0bpoqYyduYlhU0Y6WSUKHR9d9huwQhCzMXtgNQWxeQpnN4KT5_BalEW5gUw9IgCCiUrofMwSlHGBR-gElTo6WoRZg5EHcekbtuoE5rHRHb5cueyZ7UkVkvuS2S1A7wnnDadRG4mEZ1IyK5QFlW7RGt3M2l8HampWhVVSU9WONNm9yUkrDbQE0WhAzs9ZeuFNd7V_31284rk9v8UzUY8iIPEgY1OlOXyp_R72wHWv0Y9R8ErVZhyUUnCFuV4WIgdeN7sgOXanDAIkvDlv9d-A_eHo6NDebh_fPAK1po0EMpL2oDV-WxhXqN3OU837ZZm8O22dcgfpjWKTg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVIFYLyCpTiA_TUgPPYxKmEUEVZtRSqPbTS3ozjOBVlmyybXVX5L_wSfh0zzmNVqVAuPcbxOLuapz0z_gBeiywymg6qvNhL3dBLlauMTt0o8JRWuRbC2ALZ4-jgNPw8HoxX4HfXC0NllZ1NtIY6KzWdkaN2B4GFRPbf5W1ZxGh_-GH60yUEKcq0dnAajYgcmfoSt2_V-8N95PUb3x9-Ovl44LYIA67GMH7uKnSwuVAot5kOLTodV2kUGqHxc5kI00jncWQG9to9FFYeCHyL5o1nA3R9IsB178DdOEC3iboUj_vNHg8Si_ZDOxDXTzxxpbaMuh5tf1VbW-a_5YTLe71nXJ-qCvmVN0Abf4-ErUccPoD7bSjL9hrZewgrptiAta9tsn4DtkfNtdj1DjtZdnlVO2ybjZYXZteP4Ff3mNWFusApTBUZm7aDP3AxomNlzuhgY2JYVlbGPk9nqlqczcyEBZxdnFk6TT1gWdmO2uHvBWv6PWtGpaOmMnbmJaVQGNlnlC4Mg3fZXsEITsxF1UBqi2jyGE5vhadPYLUoC_MMGEZHAaWVldB5GKUo74IP0CAqjHq1CDMHoo5jUrdXqhOyx0R2tXPnsme1JFZL7ktktQO8J5w2t4rcTCI6kZBd0yyaeYme72bS-DpSU7XmqpKerHCmrfRLSFht0ieKQgd2e8o2Imsirf_77NYVye3_KbqQeBAHiQObnSjL5U_p9dwB1r9Gm0eJLFWYclFJwhnluHGIHXjaaMBybU54BEn4_N9rv4I1tB7yy-Hx0Qu411SEUInSJqzOZwvzEgPNebplNZrBt9s2IX8AULmOhA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacodynamics+and+pharmacokinetics+of+single+doses+of+prasugrel+30+mg+and+clopidogrel+300+mg+in+healthy+Chinese+and+white+volunteers%3A+an+open-label+trial&rft.jtitle=Clinical+therapeutics&rft.au=Small%2C+David+S&rft.au=Payne%2C+Christopher+D&rft.au=Kothare%2C+Prajakti&rft.au=Yuen%2C+Eunice&rft.date=2010-02-01&rft.eissn=1879-114X&rft.volume=32&rft.issue=2&rft.spage=365&rft_id=info:doi/10.1016%2Fj.clinthera.2010.02.015&rft_id=info%3Apmid%2F20206794&rft.externalDocID=20206794 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291810X00042%2Fcov150h.gif |